LRFN5 and OLFM4 in Schizoaffective Disorder

Sponsor
Elazığ Mental Health and Diseases Hospital
Study ID
NCT07447960
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Accepted

Study Details

Schizoaffective disorder (SAD) is a chronic psychiatric condition characterized by psychotic and mood symptoms. Emerging evidence suggests that Leucine-Rich Repeat and Fibronectin Type-III Domain-Containing Protein 5 (LRFN5) and olfactomedin-4 (OLFM4) may play roles in synaptic organization, neurodevelopment, and neuroinflammation. However, no prior study has investigated these biomarkers in SAD. This cross-sectional case-control study aims to compare peripheral serum levels of LRFN5 and OLFM4 in subjects diagnosed with SAD in remission and healthy control subjects. The study also assessed associations between these biomarkers and clinical symptom severity, global functioning, and systemic inflammation measured by the Aggregate Index of Systemic Inflammation (AISI). The study aimed to investigate convergent synaptic and immunoinflammatory dysregulation in SAD.

Key Dates

First listed
Mar 4, 2026
Start date
Mar 2, 2026
Status verified
Feb 2026
Primary completion
May 29, 2026
Completion
May 29, 2026

Study Design

Enrollment
120 participants (estimated)

Arms

  • Arm: Schizoaffective Disorder (SAD)
    Adult participants (18-65 years) with schizoaffective disorder according to DSM-5-TR criteria. Participants will be evaluated at baseline. No intervention will be assigned by the study protocol. Blood samples will be collected for the measurement of serum LRFN5 and OLFM4 levels and complete blood count parameters. Clinical assessments in the schizophrenia group will include the Positive and Negative Syndrome Scale (PANSS) for psychotic symptom severity, the Young Mania Rating Scale (YMRS) for manic symptom severity, and the Beck Depression Inventory (BDI) for depressive symptom severity. Sociodemographic and clinical data will be recorded for all participants.
  • Arm: Healthy Control (HC)
    Healthy control adult participants (18-65 years) without any current or past psychiatric disorder will be enrolled in the study. No intervention will be administered as part of the research protocol. Participants will undergo a baseline clinical evaluation and will provide a single blood sample for measurement of serum LRFN5 and OLFM4 levels and complete blood count parameters.

Primary Outcome Measure

Leucine-rich repeat and fibronectin type III domain-containing protein 5 (LRFN5) [ Time Frame: At hospital admission (baseline) ]

Central Contacts

Find similar trials

Nationwide
Schizophrenia trialsPsychiatry trialsMental health trialsBehavioral health trials

Related Studies